Intervention not reported
HD‐ICS (Direct evidence; 4 RCTs; 1685 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
2778 participants
Low
Respiratory‐related hospital admissions · patients with chronic obstructive pulmonary disease
It is very uncertain whether self‐management interventions changes respiratory‐related hospital admissions compared with usual care (very low certainty).
Respiratory‐related mortality · patients with chronic obstructive pulmonary disease
Self‐management interventions showed no clear difference in respiratory‐related mortality compared with usual care (low certainty).
All‐cause mortality · patients with chronic obstructive pulmonary disease
Self‐management interventions showed no clear difference in all‐cause mortality compared with usual care (low certainty).
Hospital admissions · patients with chronic obstructive pulmonary disease
Self‐management interventions showed no clear difference in all‐cause hospital admissions compared with usual care (moderate certainty).
Health status ‐ Dyspnoea · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
356 participants
Low
ED visits · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1939 participants
Low
Anxiety and depression · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1647 participants
Moderate
COPD exacerbations · patients with chronic obstructive pulmonary disease
Outcomes* · adults and children with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure ‐ need for systemic corticosteroids (ITT) · adults and children with chronic asthma
Increased showed no clear difference in treatment failure: need for systemic corticosteroids (ITT) compared with stable doses of inhaled corticosteroids (moderate certainty).
1 finding from 1 review
Treatment failure ‐ need for systemic corticosteroids (of those starting inhaler) · adults and children with chronic asthma
It is very uncertain whether increased changes treatment failure: need for systemic corticosteroids (of those… compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Unscheduled physician visits 44 weeks · adults and children with chronic asthma
Increased showed no clear difference in unscheduled physician visits 44 weeks compared with stable doses of inhaled corticosteroids (low certainty).
1 finding from 1 review
Unscheduled acute care, ED visit, or hospital admission 47 weeks · adults and children with chronic asthma
1 finding from 1 review
Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Duration of exacerbation ‐ time to symptom recovery and lung function recovery 52 weeks · adults and children with chronic asthma
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review